Refractory adult-onset Still disease complicated by macrophage activation syndrome and acute myocarditis: A case report treated with high doses (8mg/kg/d) of anakinra

Medicine (United States)

Volumn 96, Issue 24, 2017, Pages

  Parisi, Federico ^a   Paglionico, Annamaria ^a   Varriano, Valentina ^a   Ferraccioli, Gianfranco ^a   Gremese, Elisa ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

adult onset Still disease; anakinra; macrophage activation syndrome; myiocarditis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANAKINRA; ANTINUCLEAR ANTIBODY; ANTITHROMBIN III; C REACTIVE PROTEIN; CYCLOSPORIN; D DIMER; DOPAMINE; FERRITIN; FIBRINOGEN; FLUCONAZOLE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOGLOBIN; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; LEVOSIMENDAN; METHYLPREDNISOLONE; NORADRENALIN; PARACETAMOL; PIPERACILLIN PLUS TAZOBACTAM; PREDNISONE; PROCALCITONIN; TROPONIN T; VANCOMYCIN; ANTIRHEUMATIC AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ABDOMEN; ACUTE DISEASE; ACUTE MYOCARDITIS; ADULT; ADULT ONSET STILL DISEASE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ANTIBODY BLOOD LEVEL; ARTHRALGIA; ARTHRITIS; ARTICLE; BLOOD CULTURE; BLOOD GAS ANALYSIS; BONE MARROW BIOPSY; BONE MARROW TOXICITY; CASE REPORT; CHOLESTASIS; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CORONARY CARE UNIT; CORTICOSTEROID THERAPY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ECHOCARDIOGRAPHY; ERYTHROCYTE TRANSFUSION; FEMALE; FERRITIN BLOOD LEVEL; FEVER; FIBRINOGEN BLOOD LEVEL; FOLLOW UP; GENERAL CONDITION DETERIORATION; HAND PAIN; HEART ARREST; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE INJURY; HEMOGLOBIN BLOOD LEVEL; HEMOPHAGOCYTIC SYNDROME; HEPATOMEGALY; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HYPERFERRITINEMIA; HYPERTRIGLYCERIDEMIA; HYPOCAPNIA; HYPOKINESIA; HYPOXIA; INFUSION THERAPY; INOTROPISM; LEUKOCYTE COUNT; LEUKOCYTOSIS; LIVER FUNCTION TEST; LIVER NECROSIS; LYMPHOCYTE COUNT; MACROPHAGE ACTIVATION SYNDROME; MACULOPAPULAR RASH; MULTIPLE CYCLE TREATMENT; MYOCARDITIS; NEUTROPENIA; NEUTROPHIL COUNT; PANCYTOPENIA; PERICARDIAL EFFUSION; PLASMA TRANSFUSION; PLEURA EFFUSION; POLYARTHRITIS; POUCHOT SCORE; PRIORITY JOURNAL; PRURITUS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RASH; RESUSCITATION; SCORING SYSTEM; SEPSIS; SIDE EFFECT; THROMBOCYTE COUNT; TREATMENT DURATION; TRUNK; UPPER LIMB; URINALYSIS; URINARY TRACT INFECTION; URINE CULTURE; WRIST PAIN; COMPLICATION; DRUG RESISTANCE; STILL'S DISEASE, ADULT-ONSET;

ADULT; ANTIRHEUMATIC AGENTS; DRUG RESISTANCE; FEMALE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MACROPHAGE ACTIVATION SYNDROME; MYOCARDITIS; STILL'S DISEASE, ADULT-ONSET;

EID: 85021973810     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000006656     Document Type: Article

References (23)

1. Bywaters EG. Still's disease in the adult. Ann Rheum Dis 1971;30: 121-33.
2. Pouchot J, Sampalis JS, Beaudet F, et al. Adult Still's disease: manifestations, disease course, and outcome in 62 patients. Medicine 1991;70:118-36.
3. Moradinejad MH, Ziaee V. The incidence of macrophage activation syndrome in children with rheumatic disorders. Minerva Pediatr 2011;63:459-66.
4. Schulert GS, Grom AA. Macrophage activation syndrome and cytokinedirected therapies. Best Pract Res Clin Rheumatol 2014;28:277-92.
5. Ortiz-Sanjuán F, Blanco R, Riancho-Zarrabeitia L, et al. Efficacy of anakinra in refractory adult-onset Still's disease multicenter study of 41 patients and literature review. Medicine (Baltimore) 2015;94:e1554.
6. Gerfaud-Valentin M, Sève P, Iwaz J, et al. Myocarditis in adult-onset Still disease. Medicine (Baltimore) 2014;93:280-9.
7. Efthimiou P, Paik PK, Bielory L. Diagnosis and management of adult onset Still's disease. Ann Rheum Dis 2006;65:564-72.
8. Espinosa G, Cervera R. Role of biologic therapy in systemic autoimmune diseases. Med Clin 2007;128:456-7.
9. Vasques Godinho FM, Parreira Santos MJ, Canas da Silva J. Refractory adult onset Still's disease successfully treated with Anakinra. Ann Rheum Dis 2005;64:647-8.
10. Kötter I, Wacker A, Koch S, et al. Anakinra in patients with treatmentresistant adult-onset Still's disease: four case reports with serial cytokine measurements and a review of the literature. Semin Arthritis Rheum 2007;37:189-97.
11. Ortiz-Sanjuán F, Blanco R, Calvo-Rio V, et al. Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still's disease: multicenter retrospective open-label study of thirty-four patients. Arthritis Rheumatol 2014;66:1659-65.
12. Mahmud T, Hugher GR. Intravenous immunoglobulin in the treatment of refractory adult Still's disease. J Rheumatol 1999;26:2067-8.
13. Yamaguchi M, Ohta A, Tsunematsu T, et al. Preliminary criteria for classification of adult Still's disease. J Rheumatol 1992;19:424-30.
14. Pouchot J, Sampalis JS, Beaudet F, et al. Adult Still's disease: manifestations, disease course, and out come in 62 patients. Medicine (Baltimore) 1991;70:118-36.
15. Fardet L, Galicier L, Lambotte O, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol 2014;66:2613-20.
16. Giampietro C, Fautrel B. Anti-interleukin-1 agents in adult onset Still's disease. Int J Inflam 2012;2012:317820.
17. Opal SM, Fisher CJJr, Dhainaut JF, et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, doubleblind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med 1997; 25:1115-24.
18. Shakoory B, Carcillo JA, Chatham WW, et al. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial. Crit Care Med 2016;44:275-81.
19. Nordström D1, Knight A, Luukkainen R, et al. Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still's disease. An open, randomized, multicenter study. J Rheumatol 2012;39:2008-11.
20. Arca M, Fardet L, Galicier L, et al. Prognostic factors of early death in a cohort of 162 adult haemophagocytic syndrome: impact of triggering disease andearly treatment with etoposide.Br JHaematol 2015; 168:63-8.
21. Ruscitti P, Cipriani P, Ciccia F, et al. Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: analysis of 41 cases collected in 2 rheumatologic centers. Autoimmun Rev 2017;16:16-21.
22. Kullenberg T, Löfqvist M, Leinonen M, et al. Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes. Rheumatology 2016;55:1499-506.
23. OmbrelloAK,Karyl B,HoffmannPM,et al.Anescalating dose of anakinra in patients with autoinflammatory disease is a safe and reasonable therapeutic option. Arthritis Rheum 2013;65(10 Supplement): S509.